Azitra, Inc. - 8-K Filing

Azitra advances ATR-04 Phase 1/2 clinical trial to Cohort 2 following safety review committee clearance (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits (d) Exhibits)

SEC EDGAR ·

Tickers: $AZTR

Read the full article at SEC EDGAR

More Regulatory news